Race Oncology Limited (ASX: RAC) has announced the expansion of its clinical strategy with two new programs centred on Acute Myeloid Leukaemia (AML) and EGFR-mutated Non-Small Cell Lung Cancer (NSCLC). These programs build directly on the newly characterised mechanism of action of (E,E)-bisantrene and position RC220 for accelerated clinical validation across major oncology markets.

Race Oncology Limited (ASX: RAC) has reported a pivotal mechanistic discovery: its lead molecule (E,E)-bisantrene (RCDS1) primarily exerts anticancer activity by binding and stabilising G-quadruplex (G4) structures in DNA and RNA—not via an anthracycline-like pathway. The company positions this as a step-change for clinical strategy, biomarker development, and partnering.

When Race Oncology Limited’s (ASX: RAC) share price doubled at the start of last week, many investors were left asking the same question – what just happened? The answer, as is often the case with biotech catalysts, lies in a combination of significant scientific developments, strong IP positioning, and a clear signal to the market that management is preparing for the next stage of value creation.

Race Oncology Limited (ASX: RAC) has announced a major scientific breakthrough that could reshape its commercial and clinical trajectory. The company has discovered that bisantrene – a clinically validated cancer drug – exists as three photoisomers, with only the (E,E)-bisantrene form possessing significant anticancer activity. This discovery has enabled Race to file three new patent applications, potentially providing composition of matter intellectual property (IP) protecti

Race Oncology Limited (ASX: RAC) has taken another important step forward in its mission of “protecting patients while optimising their cancer treatment.” The company has now dosed the first patient in its Phase 1 trial of RC220, the reformulated version of bisantrene designed to deliver both anti-cancer efficacy and cardioprotection.